Skip to main content

Search Videos

Showing 37 - 48 of 114 results

Previous| 1... 3 | 4 | 5 ...10 |Next

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?

How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?

What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?

What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?

Can you discuss the recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the EULAR guidelines for RA? Where do IL-6 inhibitors fall into the treatment pathways?

Can you discuss the recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the EULAR guidelines for RA? Where do IL-6 inhibitors fall into the treatment pathways?

What are the side effects of TNF inhibitors and how do you manage risk for infection? And how does this side effect profile compare to that of IL-6 inhibitors?

What are the major unmet needs in patients with RA?

What are the major unmet needs in patients with RA?

What specific pattern of treatment response failures do you require to switch a patient from a TNFI to an IL-6 inhibitor of co-stimulatory blockade?

What specific pattern of treatment response failures do you require to switch a patient from a TNFI to an IL-6 inhibitor of co-stimulatory blockade?

Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?

Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?

What is the role of CCP antibodies in RA?

What is the role of CCP antibodies in RA?

What role do anti-CPP antibodies play in assessing undifferentiated arthritis? Are they predictive of responses with biologic agents? What are implications of ACPA positivity for IL-6 inhibitors?

What role do anti-CPP antibodies play in assessing undifferentiated arthritis? Are they predictive of responses with biologic agents? What are implications of ACPA positivity for IL-6 inhibitors?

Showing 37 - 48 of 114 results

Previous| 1... 3 | 4 | 5 ...10 |Next